HAPLN1 and cancer: The identification of a CH60-TLR4 complex as a HAPLN1 matrikine “sensor” that signals to mediators of inflammation, such as NF-κB, provides mechanistic insights into its pathobiological abilities and potential therapeutic targets to allay its pro-cancer contribution while preserving its native ECM function.